CalciMedica (CALC)
NASDAQ:CALC
Want to see CALC full AI Analyst Report?
CALC Stock Chart & Stats
$0.60
<$0.01(0.05%)
At close: 4:00 PM EST
$0.60
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$0.46 - $7.20
Previous CloseN/A
Volume2.29K
Average Volume (3M)71.94K
Market Cap
$9.90M
Enterprise Value$8.08M
Total Cash (Recent Filing)$13.02M
Total Debt (Recent Filing)$9.70M
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
May 18, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding15,746,416
10 Day Avg. Volume167,963
30 Day Avg. Volume71,939
Financial Highlights & Ratios
PEG Ratio-54.43
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.62K
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$10.00Price Target Upside1566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Signal In CARPO StudyThe CARPO study demonstrated a clear dose response and meaningful improvement in time to solid food tolerance in highly inflamed patients, supporting continued development of the program.
Safety Profile Context From Prior StudiesAuxora has been tested across multiple studies without prior safety signals, and analysts interpret the observed mortality imbalance as likely related to differences in patient baseline severity rather than the drug itself, which may reduce long-term safety concerns.
Strategic Focus On Acute PancreatitisAnalyst's recommendation identifies the Acute Pancreatitis program as the company's primary value driver after a strategic refocus away from the Acute Kidney Injury program, concentrating resources on the most promising asset.
Bears Say
Analyst Downgrade And Increased UncertaintyAn analyst downgraded the stock to neutral after the trial halt, citing greater uncertainty and outstanding questions about the program's future prospects.
Risk Of Spillover To Other ProgramsUncertainty remains about whether the safety issue in the kidney injury study will affect the design or commercial prospects of the acute pancreatitis and pediatric programs, posing potential broader program risk.
Trial Halt By Independent Safety CommitteeAn independent safety committee recommended stopping the KOURAGE trial for a safety concern, removing a key anticipated catalyst and creating immediate program uncertainty.
CalciMedica News
CALC FAQ
What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $0.46 and its highest was $7.20 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $9.90M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s upcoming earnings report date is May 18, 2026 which is in 8 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on Mar 03, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.268.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.28.
How many shares outstanding does CalciMedica have?
CalciMedica has 15,746,416 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went up 14.398%.
Which hedge fund is a major shareholder of CalciMedica?
Currently, no hedge funds are holding shares in CALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CalciMedica
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
CALC Stock 12 Month Forecast
Average Price Target
$10.00
▲(1566.67% Upside)
Technical Analysis
Ownership Overview
31.96% Insiders
2.77% Mutual Funds
1.04% Other Institutional Investors
63.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---